Trending...
- Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
- Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
- FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions
- Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home
- Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration
- From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners
- Tim Tebow to Headline BSI CORE Annual Summit, Bringing Nearly 400 Business Leaders Together at Bethlehem's SteelStacks
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
0 Comments
Latest on The PennZone
- ANSI BSR Upholds Appeal of AFDE Member Andrew Sulner, MSFS, JD, finding the AAFS Academy Standards Board (ASB) Violated ANSI Essential Requirements
- Prolific Press Publishes 100 Word Fiction Issue #1, the Journal's Debut Anthology
- 100 Word Fiction Releases Issue #2: Forty Stories, One Hundred Words Each
- Kentucky's Plane Crash Data Lands Far from the State's Busiest Airports
- StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
- Netberg Announces the Aurora X2 Switch Series, Built on Xsight Labs' Programmable X2 Silicon
- Imagen Golf Named Exclusive Golf Instruction Partner at Wood Lane Golf and Social
- Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
- Heidi G. Villari of The Villari Firm, PLLC Recognized in The Best Lawyers in America 2027 for Construction Law and Personal Injury Litigation
- When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
- Nearly One-Third of CRE Asset Managers Make Major Capital Decisions on Gut Instinct, New Survey Finds
- RemoteBridge Names Dr. John N. Just, Ed.D. Chief Executive Officer
- Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
- New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
- Grace Montessori School Earns Prestigious American Montessori Society Accreditation
- Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
- Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
- NaturismRE expands international research programme with Health & Wellbeing Survey
- L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach